Trial Profile
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 28 Feb 2018 Status changed from recruiting to discontinued.
- 23 Dec 2016 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 23 Dec 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.